(Q55463295)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

Adaptive radiation therapy

26 January 2020

main subject

0 references

phase III clinical trial

0 references

1 reference

0 references

1 reference

T de La Motte Rouge

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

N Moore

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

A Zeaiter

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

A Das

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

H Phillips

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Z Modrusan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

English

0 references

publication date

14 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

334-340

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12325-011-0007-3

26 January 2020

exact match

0 references

cites work

Glioblastoma multiforme: a review of where we have been and where we are going

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Epidemiology of brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-011-0007-3

10.1007/S12325-011-0007-3

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21432029%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

26 January 2020

1037365997

0 references

1 reference